<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708587</url>
  </required_header>
  <id_info>
    <org_study_id>1-2020-0073</org_study_id>
    <nct_id>NCT04708587</nct_id>
  </id_info>
  <brief_title>Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)</brief_title>
  <official_title>Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective randomized clinical trial is to compare the clinical outcomes&#xD;
      according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet&#xD;
      therapy after percutaneous coronary intervention in patients with advanced chronic kidney&#xD;
      disease using a new generation drug eluting stents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, open label, multicenter randomized clinical trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net Clinical adverse event (NACE)</measure>
    <time_frame>1 year</time_frame>
    <description>Net Clinical adverse event (NACE) : all cause death, myocardial infarction, stent thrombosis, stroke, major bleeding (BARC 3,5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of Each component of NACE</measure>
    <time_frame>1 year</time_frame>
    <description>NACE : all cause or Cardiac death, myocardial infarction, stent thrombosis (definite, probable, possible), stroke (non-ischemic, ischemic), major bleeding (BARC 3,5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of key secondary efficacy endpoint : Major Efficacy end points</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac death, myocardial infarction, stent thrombosis (definite or probable), stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of key secondary safety endpoint : Major safety end points</measure>
    <time_frame>1 year</time_frame>
    <description>BARC bleeding (2,3,5), Fatal bleeding or intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Target lesion revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Target vessel revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Subgroup analysis of primary endpoint, key secondary efficacy, safety endpoint and, revascularization according to the CKD stage (lllb vs. iV or V)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Subgroup analysis of primary endpoint, key secondary efficacy, safety endpoint and, revascularization according to the clinical presentation (stable angina vs. acute coronary syndrome)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Subgroup analysis of primary endpoint, key secondary efficacy, safety endpoint and, revascularization according to the type of Stent (polymer free vs. durable polymer)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>dual anti-platelet therapy at least 6 months</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dual anti-platelet therapy 3months or less</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dual anti-platelet therapy at least 6 months</intervention_name>
    <description>Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.</description>
    <arm_group_label>dual anti-platelet therapy at least 6 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dual anti-platelet therapy 3months or less</intervention_name>
    <description>Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.</description>
    <arm_group_label>dual anti-platelet therapy 3months or less</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Over 19 years old&#xD;
&#xD;
          2. Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR &lt;45 / &lt;30 / &lt;15 or dialysis)&#xD;
&#xD;
          3. Patients treated with a new generation drug eluting stent.&#xD;
&#xD;
          4. Patients who signed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Over 85 years old&#xD;
&#xD;
          2. Patients with high risk of bleeding 1) History of hemorrhagic stroke 2) Stroke,&#xD;
             dementia or central nervous system damage within 1 year 3) Head trauma or brain&#xD;
             surgery within 6 months 4) Tumor in the skull 5) If aortic dissection is suspected 6)&#xD;
             Internal bleeding within 6 weeks 7) In case of active bleeding or bleeding disorder 8)&#xD;
             In case of major surgery, trauma or bleeding within 3 weeks&#xD;
&#xD;
          3. Patients who need oral anticoagulant&#xD;
&#xD;
          4. Pregnant women or women of childbearing age&#xD;
&#xD;
          5. Life expectancy is less than 1 year&#xD;
&#xD;
          6. Patients with a history of intracranial bleeding&#xD;
&#xD;
          7. Moderate to severe hepatic impairment (Child-Pugh class B or C)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Sun Kim, MD, PhD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-Sun Kim, MD, PhD, FESC</last_name>
    <phone>82)-2)-2228-8457</phone>
    <email>KJS1218@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-Sun Kim, MD, PhD, FESC</last_name>
      <phone>82)-2)-2228-8457</phone>
      <email>KJS1218@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-platlet therapy</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>new generation drug eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

